JO
OACC

John Overdeck’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

John Overdeck’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.68M Hold
437,500
– – ﹤0.01% 2210
2026
Q1 		$4.63M Hold
437,500
– – ﹤0.01% 2047
2025
Q4 		$4.63M Hold
437,500
– – 0.01% 1780
2025
Q3 		$4.6M Hold
437,500
– – 0.01% 1530
2025
Q2 		$4.57M Hold
437,500
– – 0.01% 1274
2025
Q1 		$4.48M Hold
437,500
– – 0.01% 1189
2024
Q4 		$4.36M Buy
+437,500
New +$4.37M 0.01% 1190

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

John Overdeck's OACC Position: Q2 2026 in Review

John Overdeck held its Oaktree Acquisition Corp III Life Sciences (OACC) position steady in Q2 2026 at 437,500 shares worth $4.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2210.

John Overdeck first reported a position in OACC in Q4 2024 and has held it in 7 quarters since. 50 funds tracked by Wall St. Rank hold OACC as of Q2 2026.

  • John Overdeck held 437,500 shares of Oaktree Acquisition Corp III Life Sciences worth $4.68M as of Q2 2026.
  • John Overdeck left its Oaktree Acquisition Corp III Life Sciences share count unchanged in Q2 2026.
  • Oaktree Acquisition Corp III Life Sciences made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2210 holding.
  • John Overdeck first reported a position in Oaktree Acquisition Corp III Life Sciences in Q4 2024 and has held it in 7 quarters since.
  • 50 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.